Endologix, Inc. (Endologix), a California-based developer and manufacturer of minimally invasive treatments for vascular diseases, has appointed Daniel Hawkins to the newly created position of vice president of global marketing, with immediate effect. Hawkins has above 15 years of marketing management and business development experience in the medical device and biotechnology industries.
Hawkins spent his recent seven years in founder and leadership roles developing and commercializing medical devices for incubators funded by Three Arch Partners, Frazier Healthcare, Prospect Ventures, MPM Capital and Charter Ventures.
Hawkins is a founder of Calibra Medical Inc. He has also played critical roles in developing product and marketing strategies for Restore Medical, Inc. and EnteroMedics, Inc. Prior to that, he created the marketing and sales department and played critical product development roles at Intuitive Surgical, Inc.
He holds a Masters in Business Administration from the Stanford Graduate School of Business and a Bachelors of Science in Economics from The Wharton School at the University of Pennsylvania.
“Daniel brings a successful track record of developing and launching new medical technologies,” said John McDermott, Endologix president and chief executive officer. “He is a results-oriented leader with wide-breadth experience who will strengthen our senior management team and drive our new product development portfolio and business development activities. Daniel also has a strong commercial background that will be instrumental in achieving continued market share gains and support the successful commercialization of our Powerlink XL, our suprarenal proximal extensions and the recently introduced IntuiTrak Delivery System.”
Hawkins commented, “Innovative products such as the IntuiTrak are a testament to the strength of Endologix’s product development team and are the foundation for profitable growth. I’m excited about joining the senior management team at Endologix to lead the commercialization of existing products as well as pursuing product development opportunities.”